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Background:
Many hospitalized patients with respiratory failure are treated with non-invasive positive
pressure ventilation (NiPPV). In many cases non-invasive ventilation can be used to successfully
treat patients and subsequently avoid endotracheal intubation. Recent literature and clinical
practice have shown that in patients who are protecting their airway, and in whom the pH is not
dangerously low, the use of non-invasive positive pressure ventilation can be effective (1).
Additional studies argue that NiPPV in more severely ill patients (pH < 7.2) with chronic
obstructive pulmonary disease (COPD) is no worse than endotracheal intubation (2,3) with
regard to mortality, lengths of stay and readmission rates. Furthermore, better outcome was
confirmed for patients who succeeded NiPPV and avoided endotracheal intubation. Thus, the
non-invasive mode of ventilation can assist patients in ventilating equally or more effectively,
and in many cases can be used to avoid the more invasive endotracheal intubation.
Many studies have evaluated treatment failures of NiPPV. Failure rates range from 30-80%
depending on the cause of respiratory failure and underlying medical condition(s) of patient
population (4). Other studies have looked at factors which predict NiPPV failure, such as
physiologic scoring (age, severity of underlying illness) and presence of acute respiratory
distress syndrome (ARDS) or community acquired pneumonia (CAP) (5). Having an objective
and real time means of early identification of patients that will fail NiPPV would greatly benefit
patients by helping physicians intervene early with endotracheal intubation when indicated.
The current modality of evaluating patients with respiratory failure on NiPPV is via analysis of
arterial blood gas (ABG). Arterial blood is obtained via invasive radial or femoral artery
puncture, and in some cases arterial catheters are placed to allow for frequent ABGs. Treating
physicians may use ABG data (PaCO2 and PaO2 values) to make adjustments to NiPPV settings
(ie, adjustment to IPAP or EPAP, inspiratory/expiratory positive airway pressure). Over time,
data trends of ABG analytes may be followed and adequacy of ventilator therapy can be
assessed. During successful treatment with NiPPV guided by ABG assessment, clinicians may
adjust NiPPV settings, or physicians may change modes of ventilation. Improvements in trends
of ABG data resulting from successful treatment may lead to discontinuation of NiPPV in favor
of face-mask or nasal cannula oxygen delivery. If ABG values trend in a worsening direction,
NiPPV may viewed as a treatment failure and the patient may require intubation and mechanical
ventilation.
It would be preferable to provide early identification of patients for whom NiPPV is likely to
fail, and to do so without performing and waiting for the results of ABG analysis. ABG analysis
is invasive, expensive and slow to respond to changes in NiPPV therapy settings. Additionally,
the routine use of indwelling arterial catheters (IAC) for ICU patients has recently been
challenged since the information IACs provide can almost always be obtained without them and
they introduce risk of blood infection and vascular complications (6). Ideally, noninvasive
measures of patient status could be used to predict future success or failure of NiPPV therapy in

a more timely fashion. In addition, it would be beneficial to avoid ABG analysis in space and
NASA headquarters could monitor trends more easily with a non-invasive system.
One noninvasive parameter that is an indicator of PaCO2 is end-tidal CO2 (etCO2). End-tidal
CO2 is obtained by analyzing the CO2 concentration in the expired gas. It is assumed that a gas
sample taken at the end of expiration, or end-tidal gas, is pure alveolar gas and that the CO2
concentration is indicative of the arterial CO2 level. Prior studies have compared ABG PaCO2
values to EtCO2 values, though much of the literature involves intubated patients on mechanical
ventilation. The data on the correlation between PetCO2 and PaCO2 values in intubated patients
has been mixed (7, 8), though much of the literature shows that the correlation is not strong and
argues against the use of PetCO2 monitoring in this patient population (9).
In mainstream volumetric capnography (MVC) the infrared measurement takes place at the
airway, in line with the respiratory gas stream. The capnometer interfaces directly with extension
tubing inserted into the NiPPV circuit without altering the airflow or NiPPV mask fit. The
lightweight and easy to use device can easily be attached to the NiPPV system without any
detriment or discomfort to the patient. The infrared data signal could then be passed via electrical
cable directly to the ventilator providing the positive pressure. Some noninvasive ventilators are
already equipped with an input for capnometer data.
To our knowledge, no prior studies have exclusively evaluated patients on NiPPV in assessing
the use of mainstream volumetric capnometry monitoring. It is not known whether the use of
mainstream volumetric capnography monitoring is useful in the management of patients with
respiratory failure on NiPPV.
Patient Selection Criteria:
The population evaluated was patients with respiratory distress or respiratory failure who are on
non-invasive positive pressure ventilation and are inpatients in the medical intensive care unit
(MICU), the surgical intensive care unit (SICU), the neurologic critical care unit (NCC), the
intermediate care unit (IMCU) or the Huntsman Hospital ICU (HICU) at the University of Utah
Hospital. Any patient on noninvasive ventilation at any time during the hospitalization may be
considered. This includes intubated patients on invasive mechanical ventilation who may be
extubated to NiPPV. A total of 60-120 subjects will be studied prospectively. All patients will
be monitored using mainstream volumetric CO2. Monitoring will be conducted in the MICU,
SICU, NCC, HICU and IMCU. After a research team member discusses the study with the
patient or medical decision making representative and invites the patient to participate, the
patient will be allowed as much time as necessary to decide whether or not to participate.
Exclusion Criteria:
1. Age < 18
2. Pregnant women
3. Patient’s inability to tolerate NiPPV mask
4. Prisoners
5. Lack of informed consent
6. Use of a NiPPV mask that does not completely cover the mouth and nose (ie nasal pillows)
7. Attending Physician feels enrollment could interfere with optimal patient care

8. Patient is Do Not Intubate (DNI)
9. V60 ventilator not available for NiPPV
Instrumentation and Patient Set-Up:
The mainstream volumetric CO2 collecting device will be the Capnostat® 5 (Philips
Respironics, Wallingford, CT). The device measures CO2 in the NiPPV tubing via infrared
spectroscopy. The Capnostat 5 may either be attached to a mouthpiece for a PetCO2
measurement or attached to a tube extension that is placed inline between the NiPPV tubing and
mask. A new mouthpiece collecting device and extension tubing will be used for each patient.
Each new device will be calibrated prior to data collection for each patient. The Capnostat 5 will
be connected to the NM3 Volumetric Capnometer (Phillips-Respironics, Wallingford, CT) by the
signal cable and pressure sensing tubing.
Enrolled patients will have their mask fitted according to the judgment of the respiratory
therapist (RT) which is the current standard; the investigators will not be involved in mask
selection. If the patient has already been enrolled at the time of initiation of BiPAP ventilation,
immediately prior to placement of the mask and initiation of non-invasive ventilation, the patient
will be asked to breathe for several breaths via a mouthpiece connected to the Capnostat 5 sensor
in order to establish a reference PetCO2 measurement. After a mask is selected and fitted, the
study team will record the mask type and size.
The patients will be ventilated using the V60 BiPAP ventilator (Phillips).
If the clinical team allows the patient to remove the non-invasive mask at any time
(administration of medications, mask breaks, etc), we will request the patient to breathe normally
for several breaths directly into the Capnostat 5 sensor via mouthpiece.

The patient will be asked to wear an additional pulse oximeter finger probe that will be
connected to the NM3 for collection of peripheral oxygen saturation (SpO2) and heart rate. By
default the screen of the NM3 to not be readily accessible/viewable to the clinician since she/he
likely already has an available display monitor for heart rate and peripheral oxygen saturation.
However, if the clinician feels it is in the best interest in the patient to view the NM3 display
screen he/she may do so. There is no guarantee that the heart rate and saturation displayed on
screen accurately represent true clinical parameters.
There will be no use of investigational devices in this study.
We anticipate there will be study patients enrolled after NiPPV has already been initiated for
respiratory distress/failure. After consent is obtained and patients are enrolled, we will request
that the RTs assist us in placing the Capnostat 5 sensor inline to ensure there is no adverse
impact on patient therapy by the brief (<5 second) disconnect of the ventilation circuit.
Measurement of end-tidal CO2 (etCO2) during noninvasive positive pressure ventilation is
difficult because of gas mixing in the mask, loss of expired gas due to leak and dilution of the
expired gas by ventilator flow during expiration. We have tried a number of methods to

compensate for these error sources including placing the sample port near the patients nose and
periodically disabling the ventilator flow during expiration. Neither of these methods allows for
measurement of the volume of excreted CO2 (VCO2) along with etCO2. We have also pursued
a method of mathematically compensating for the effect of gas mixing and leak so that etCO2
and VCO2 can be calculated from the CO2 and flow signals obtained by placing volumetric
capnography sensors (flow and CO2) between mask port and the exhalation port during NPPV.
Earlier tests have demonstrated that this compensation method works when tested using a mock
patient setup on the bench. In bench tests we can directly measure the true etCO2 by placing a
second sensor in the simulated trachea. In bench tests we have been able to successfully
compensate for the effects of mask leak and gas mixing in the mask using the following equation
to calculate etCO2:
etCO2comp = etCO2raw/[1-exp(-TV/Vmask)]
Where:
etCO2comp is the compensated end tidal CO2 value
etCO2raw is the end tidal CO2 measured at the mask port without any compensation,
TV is non-leak compensated expired tidal volume as measured at the mask port and
Vmask is the volume of the space between the patient’s face and the mask.
This model assumes that the mask volume represents a perfect mixing chamber and that mixing
in the mask is a first-order system where the volume of the mask equals one time (volume)
constant.
Testing this method is more challenging in a clinical setting. The first problem is that we cannot
directly measure the true etCO2. We can only periodically measure the partial pressure of
arterial CO2 (PaCO2) by taking an arterial blood gas sample. PaCO2 is similar to etCO2 in
normal healthy patients who do not have severe ventilation perfusion (V/Q) mismatch problems.
In most cases, it is expected that the etCO2 would be less than the PaCO2 and should sometimes
be much less than PaCO2 depending on the severity of the lung disease.
Arterial blood gas samples:
We will request that patients allow the collection of two ABG. If the patients already have an
indwelling arterial catheter (IAC) the two ABGs will be drawn from the catheter to avoid
additional arterial punctures. If the patients do not have IACs we will have the pulmonary lab
technicians perform the arterial punctures to obtain the ABGs.
We will not recommend or encourage the placement of IAC by clinicians. We will not
recommend or encourage any additional lab draws other than the two post enrollment blood
gases. The first ABG will be approximately one hour (60 minutes) after enrollment and the other
approximately two hours after the first (180 minutes after enrollment). The cost of these ABGs
will be covered as part of the study expenses. If the clinical team has ordered an ABG
independent of our study protocol within +/- 30 minutes of our expected draw, we will forego the
study protocol ABG to avoid additional arterial punctures and/or additional loss of blood.

The clinical team (including the attending physician) will be preferentially blinded to the results
of the study protocol ABGs. We believe the blinding is necessary to prevent alteration in normal
clinical behavior due to increased availability of ABG data which would not normally have been
available. However, if any ABG results meet critical criteria, the values will be reported to the
clinical team as they normally would per policy. For example, any pH ≤ 7.25 or ≥ 7.6, PaCO2 ≤
20 or ≥ 60 mmHg, PaO2 ≤ 40 will be called to the clinical team.
If enrollment occurs sometime after initiation of NiPPV, then both study ABGs would be for
research purposes only. This assumes that the patient is tolerating the NiPPV well and not
demonstrating concerning clinical signs that would otherwise warrant an ABG request.
Variables to be Recorded:
The NM3 monitor will record mainstream volumetric CO2, airway pressure, pulse oximeter and
heart rate data. The V60 ventilator calculates ventilation related variables, such as, but not
limited to, return tidal volume (Tv), leak rate, set pressures (IPAP, EPAP), respiration rate (R),
set FiO2, and peak pressures. NiPPV variables can either be transmitted via cable to a personal
computer in the case of the V60 ventilator or recorded from the display screen of the NiPPV
ventilator. Data for the NM3 is collected at 100 Hz and the V60 at 50 Hz and stored on a laptop
computer.
Additional data (lab values and vitals) will be recorded or retrieved from the patient medical
chart (Powerchart). These data include, but are not limited to, diagnosis, body temperature, blood
gas values, temperature (T), pulse rate (P), blood pressure (BP), and oxygen saturation (SpO2).
Examples of laboratory values which will be retrieved from the patient chart will include serum
creatinine, bilirubin, lactate, and venous and arterial pH. If the clinical staff collects any body
temperature, blood gas values, or vital signs during the data collection session, we may also
record or retrieve those values. We will also record any treatments administered to the patient
during the study as chosen by the clinical staff. We will not recommend or take part in clinical
decision making based on the non-invasive CO2 measurements that are observed or recorded.
Results: In analyzing the data from the first 7 test patients for whom PaCO2 measurements were
available we found the following results:

Mask Type
Full Face
Mouth and Nose
Combined data

Average
uncompensated
difference
(raw etCO2 – PaCO2)
-38.1 ± 22.3.8 mm Hg
-29.6 ± 6.9 mm Hg
-33.8±16.5 mm Hg

Average -compensated
etCO2 difference
(comp etCO2 – PaCO2)
-4.6±7.8 mm Hg
-6.5±12.8 mm Hg
-5.6±10.3 mm Hg

There were 15 total blood gas comparisons in the data set, 8 were in patients with full face NPPV
masks and 7 with a nose and mouth mask. The plot below shows the results when compensated
etCO2 is plotted against PaCO2
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Conclusions:
The overall average error appears to be effectively compensated using this method. There
appears to be a correlation between the etCO2 and PaCO2; however, if one of the patients that
had a high PaCO2 is removed, there is no correlation in the data. The method seems to do an
acceptable job in processing noisy clinical data. It also requires a combination flow and CO2
sensor placed between the mask and the exhalation port. This is beneficial for astronauts in that
their ventilation status can be accurately monitored in space. There is currently more data being
collected for further analysis.

References and Appendices
1. ATS Consensus. ATS international consensus conference in ICU medicine: non-invasive
positive pressure ventilation in acute respiratory failure. American Journal of Respiratory and
Critical Care Medicine 2000; 163: 282-291.
2. Conti et al. Non-invasive vs. conventional mechanical ventilation in patients with chronic
obstructive pulmonary disease after failure of medical treatment in the ward. A randomized trial.
Intensive Care Med 2002; 28:1701-1707.
3. Squadrone et al. Noninvasive vs. Invasive ventilation in COPD patients with severe acute
respiratory failure deemed to require ventilatory assistance. Intensive Care Med 2004; 30:13031310.
4. Hill et al. Noninvasive ventilation in acute respiratory failure. Critical Care Medicine 2007;
35: 2402-2407.
5. Antonelli et al. Predictors of failure of noninvasive positive pressure ventilation in patients
with acute hypoxemic respiratory failure: a multi-center study. Intensive Care Med 2001
Nov;27(11):1718-28.
6. Garland et al. Indwelling Arterial Catheters in the Intensive Care Unit: necessary and
beneficial, or a harmful crutch? American Journal of Respiratory and Critical Care Medicine
2010 Vol. 182:133-134.
7. Ozlu et al. Comparison of End-tidal CO2 and ABG analysis in paediatric patients undergoing
controlled ventilation with a laryngeal mask or a face mask. Paediatric Anaesthesia 1999; 9:
409-413.
8. Prause et al. A comparison of end-tidal CO2 documented by capnometry and the arterial
pCO2 in emergency patients. Resuscitation 1997; 35(2): 145-148.
9. Hoffman et al. End-tidal carbon dioxide in critically ill patients during changes in mechanical
ventilation. American Review of Respiratory Diseases 1989; 140(5): 1265-1268.
10. Barton et al. Correlation of end-tidal CO2 measurements to arterial PaCO2 in nonintubated
patients. Annals of Emergency Medicine 1994; 23(3): 560-563.
11. Lahn et al. End-tidal CO2 Determination to predict PaCO2 in Emergency Department
Asthmatics. Academy of Emergency Medicine 2003; 10:566.
12. Liu et al. Accuracy of capnography in nonintubated surgical patients. Chest 1992; 102: 15121515.
13. Yosefy et al. End-tidal carbon dioxide as a predictor of the arterial pCO2 in the emergency
department setting. Emergency Medical Journal 2004; 21: 557-559.

14. Lenz et al. Capnography for continuous postoperative monitoring of non-intubated,
spontaneously breathing patients. Journal of Clinical Monitoring and Computing 1991; 7(3):
245-248.
15. http://www.oridion.com/eng/products/sampling-lines/sampling-lines.asp
16. Waugh et al. Capnography enhances surveillance of respiratory events during procedural
sedation: a meta-analysis. Journal of Clinical Anesthesia 2011 May;23(3):189-96.

